Table: Aska Pharmaceutical Holdings -Q1 group results
02/08/2021 07:00
Aug 2 (Reuters)-
Aska Pharmaceutical Holdings Co., Ltd.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
3 months ended 3 months ended Year to
Jun 30, 2021 Jun 30, 2020 Mar 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 14.22 52.00
Operating 1.19 1.50
Recurring 1.33 1.50
Net 1.10 800 mln
EPS 38.72 yen 29.33 yen
Ann Div 14.00 yen
-Q2 div 7.00 yen
-Q4 div 7.00 yen
NOTE - Aska Pharmaceutical Holdings Co., Ltd..
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T
Recent news on ASKA Pharmaceutical Holdings
See all newsTable: Aska Pharmaceutical Holdings -Q1 group results
Brief: Dalton Investment Strongly Oppose Conditional Activation Of Countermeasures Announced By Aska Pharmaceutical Holdings On May 25
Brief: Aska Pharmaceutical -Plan To Put To Shareholders Proposal On Countermeasures Against Potential Large-Scale Share Purchase By Dalton And Related Parties
Table: Aska Pharmaceutical Holdings -2025/26 group results
Table: Aska Pharmaceutical Holdings -2025/26 group results